Full-Time

VP – Lifecycle & Pipeline

Oncology Business Unit

Confirmed live in the last 24 hours

Deadline 7/1/25
AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

Compensation Overview

$330.3k - $495.4k/yr

+ Short-term incentive bonus + Equity-based long-term incentive program

Senior, Expert

Cambridge, UK + 1 more

More locations: Gaithersburg, MD, USA

This position requires a minimum of three days per week in the office, indicating a hybrid work model.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Post-graduate degree in biological, chemical, or pharmacological sciences
  • Experience in oncology drug development process and necessary scientific, commercial and strategic considerations
  • Experience in articulating the commercial and strategic risk assessments of clinical trial designs
  • Experience in value-risk assessment modelling
  • Proven experience in pharmaceutical industry or consulting in which you have contributed to the global pipeline strategy e.g. market assessment, competitor analysis, forecasting
  • Previous strategy role contributing to investment decisions – tumor strategy or pipeline strategy
  • Working with data and/or a science research/ bio-pharmaceutical environment
  • Understanding of general business and core marketing principles and application to future healthcare market challenges
Responsibilities
  • Oversee the Lifecycle and Pipeline team within the Oncology Business Unit, fostering a high-performance culture that aligns with our strategic objectives for long-term growth and improved patient outcomes
  • Collaborate with cross-functional teams and senior stakeholders within the Oncology Business Unit and R&D to formulate and execute commercialization strategies
  • Enable strategic and data-based decision-making by analyzing and applying meaningful data from diverse internal and external sources
  • Provide strategic guidance to support complex investment decisions by developing robust business cases aligned with AstraZeneca’s core strategies, supported by accurate data and analytics
Desired Qualifications
  • Candidates may have clinical or investor background or may possess an MBA, but not required
  • Awareness of the highly competitive cancer therapeutic marketplace including the many new technologies that are being developed across the industry (Preclinical and Clinical)
  • Experience assessing oncology portfolios and advising internal/external clients on how to best position themselves for success

AstraZeneca focuses on discovering, developing, and selling prescription medicines. The company specializes in three main areas: Oncology, which deals with cancer treatment; Cardiovascular, Renal & Metabolism, which addresses heart, kidney, and metabolic diseases; and Respiratory & Immunology, which targets lung and immune system diseases. Their products are developed through extensive research and development, followed by clinical trials and regulatory approvals before they reach the market. AstraZeneca differentiates itself from competitors by investing heavily in scientific research and forming strategic partnerships to enhance drug discovery. Their goal is to advance healthcare by providing effective treatments for serious diseases while collaborating with the scientific community to improve their research capabilities.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EsoBiotec enhances AstraZeneca's cell therapy capabilities and market position.
  • New manufacturing facilities in Rockville and Wuxi expand AstraZeneca's production capacity globally.
  • Positive trial results for Enhertu strengthen AstraZeneca's competitive edge in oncology.

What critics are saying

  • Increased competition in oncology may impact AstraZeneca's market share.
  • Potential regulatory delays could affect the launch of new therapies.
  • High operational costs of new facilities may strain AstraZeneca's financial resources.

What makes AstraZeneca unique

  • AstraZeneca focuses on three main therapy areas: Oncology, Cardiovascular, and Respiratory.
  • The company invests heavily in R&D to create innovative drugs and therapies.
  • AstraZeneca's A.Catalyst Network fosters global collaboration and innovation in healthcare.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Cision
May 20th, 2025
Acquisition Of Esobiotec Completed

20 May 2025 Acquisition of EsoBiotec completed AstraZeneca today announced the successful completion of the acquisition (https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-acquire-esobiotec.html) of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients access to transformative cell therapy treatments delivered in just minutes rather than the current

BioBuzz
May 12th, 2025
AstraZeneca Opens New Cell Therapy Manufacturing Facility in Rockville, Signaling Major Boost to Maryland's Biotech Economy

In collaboration with general contractor CRB, a life sciences design and construction firm, AstraZeneca embedded operational redundancy and agility into every layer of the facility's architecture.

The Pharma Letter
May 12th, 2025
AstraZeneca breaks ground on $475 million drug plant in Wuxi

AstraZeneca breaks ground on $475 million drug plant in Wuxi.

MocoShow
May 9th, 2025
AstraZeneca Opens $300 Million CAR-T Manufacturing Facility in Rockville, Creating Over 150 Jobs

AstraZeneca opens $300 million CAR-T manufacturing facility in Rockville, creating over 150 jobs.

Cision
May 9th, 2025
Imfinzi Improved Dfs In Early Bladder Cancer

Imfinzi improved DFS in early bladder cancer